Format

Send to

Choose Destination
Biomed Pharmacother. 2010 Apr;64(4):240-8. doi: 10.1016/j.biopha.2009.06.019. Epub 2009 Oct 27.

GMDP augments antitumor action of the CP/TNFalpha combination in vivo.

Author information

1
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Mikhlukho-Macklaya street, Moscow 117997, Russian Federation. petrova@ibch.ru

Abstract

We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-alpha (TNFalpha) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFalpha and GMDP and also the conditions of the drugs combination injection provided 100% survival of mice with Ehrlich ascites carcinoma were found. Furthermore, it was shown first that GMDP has been decreased toxicity of the cisplatin/TNFalpha combination and normalized the changes in the experimental mice hematological parameters which were produced by the CP/TNFalpha combination.

PMID:
19932583
DOI:
10.1016/j.biopha.2009.06.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center